[A23-116] Vosoritide (achondroplasia, ≥ 4 months) – Benefit assessment according to §35a Social Code Book V
Last updated 01.03.2024
Project no.:
A23-116
Commission:
Commission awarded on 28.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Muscles, bones and joints
Indication:
Patients with achondroplasia 4 months to < 2 years of age
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A23-116_en
| Project no. | Title | Status |
|---|---|---|
| A23-92 | Vosoritide (achondroplasia, ≥ 2 years) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| G21-29 | Vosoritide (achondroplasia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |